Shaanxi Eye Hospital, Xi'an People's Hospital (Xi'an Fourth Hospital), Affiliated People's Hospital, Northwest University, Xi'an, 710004, Shaanxi Province, China.
Department of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Mol Aspects Med. 2023 Dec;94:101220. doi: 10.1016/j.mam.2023.101220. Epub 2023 Oct 17.
Glaucoma is the leading cause of irreversible blindness worldwide. Currently the only effective treatment for glaucoma is to reduce the intraocular pressure, which can halt the progression of the disease. Highlighting the importance of identifying individuals at risk of developing glaucoma and those with early-stage glaucoma will help patients receive treatment before sight loss. However, some cases of glaucoma do not have raised intraocular pressure. In fact, glaucoma is caused by a variety of different mechanisms and has a wide range of different subtypes. Understanding other risk factors, the underlying mechanisms, and the pathology of glaucoma might lead to novel treatments and treatment of underlying diseases. In this review we present the latest research into glaucoma including the genetics and molecular basis of the disease.
青光眼是全球导致不可逆性失明的主要原因。目前，治疗青光眼唯一有效的方法是降低眼内压，从而阻止疾病的进展。强调识别有发生青光眼风险的个体和早期青光眼患者的重要性，有助于患者在视力丧失前接受治疗。然而，有些青光眼病例的眼内压并没有升高。事实上，青光眼是由多种不同的机制引起的，具有广泛的不同亚型。了解其他危险因素、潜在机制和青光眼的病理学可能会导致新的治疗方法和潜在疾病的治疗。在这篇综述中，我们介绍了包括疾病的遗传学和分子基础在内的青光眼的最新研究进展。
